Antiproliferative effect of an analog of curcumin bis-1,7-(2-hydroxyphenyl) -hepta-1,6-diene-3,5-dione in human breast cancer cells

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 14, 2012, Pages 1900-1907

  Kumaravel, M ^a   Sankar, P ^a   Rukkumani, R ^a  

^a PONDICHERRY UNIVERSITY   (India)

Author keywords

BDMC A; Breast cancer; Curcumin; MCF 7; MTT

Indexed keywords

BIS 1,7 2(HYDROXYPHENIL) HEPTA 1,6 DIENE 3,5 DIORE; CURCUMIN; CYCLIN D1; CYTOTOXIC AGENT; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; L-LACTATE DEHYDROGENASE; MCF-7 CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874068612     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. MATES JM, SEGURA JA, ALONSO F.J., MÁRQUEZ J. Anticancer antioxidant regulatory functions of phytochemicals. Curr Med Chem 2011; 18: 2315-2338.
2. BAR-SELA G., EPELBAUM R, SCHAFFER M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17: 190-197.
3. SHEHZAD A, KHAN S, SHEHZAD O., LEE YS Curcumin therapeutic promises and bioavailability in colorectal cancer. Drugs Today (Barc) 2010; 46: 523-532.
4. DORAI T, AGGARWAL BB Role of chemopreventive agents in cancer therapy. Cancer Lett 2004; 215: 129-140.
5. PARK MJ, KIM EH, PARK I.C., LEE HC, WOO SH, LEE JY, HONG Y.J., RHEE CH, CHOI SH, SHIM BS, LEE S.H., HONG SI Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1, and p53. Int J Oncol 2002; 21: 379-383.
6. GARCEA G, BERRY DP, JONES D.J., SINGH R., DENNISON AR, FARMER PB, SHARMA RA, STEWARD W.P., GESCHER AJ Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120-125.
7. SHEN L, JI HF Theoretical study on physicochemical properties of curcumin. Spectrochim Acta A Mol Biomol Spectrosc 2007; 67: 619-623.
8. YAMAKOSHI H, OHORI H, KUDO C., SATO A, KANOH N, ISHIOKA C., SHIBATA H, IWABUCHI Y. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorgan Med Chem 2010; 18: 1083-1092.
9. ANTO RJ, KUTTAN G, DINESH BABU KV, RAJASEKHARAN KW, KUTTA NT Antitumor and free radical scavenging activity of synthetic curcuminoids. Int J Pharm 1996; 131: 1-7.
10. DINESH BABU K.V., RAJASEKHARAN KN Simplified conditions for the synthesis of curcumin I and other curcuminoids. Org Prep Proced Int 1994; 26: 674-677.
11. MOSSMAN T. Rapid colorimetric assay for cellular growth and survival: A application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
12. KING J. Practical Clinical Enzymology. D. Van. Nostrand Company Ltd., 1965: pp. 83-93.
13. AGGARWAL B, SHISHODIA S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421.
14. KUNNUMAKKARA AB, ANAND P, AGGARWAL BB Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
15. SHAO ZM, SHEN ZZ, LIU C.H., SARTIPPOUR MR, GO VL, HEBER D, NGUYEN M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 2002; 98: 234-240.
16. XIA Y, JIN L, ZHANG B., XUE H, LI Q, XU Y. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 2007; 80: 2161-2169.
17. CHIU TL, SU CC Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 2009; 23: 469-475.
18. PHILAN GA, DOXSEY SJ The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 1999; 9: 289-302.
19. SHERR CJ. D-type cyclins. Trends Biochem Sci 1995; 20: 187-190.
20. MUKHOPADHYAY A, BANERJEE S, STAFFORD L.J., XIA C., LIU M, AGGARWAL BB Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21: 8852-8861.
21. DEVASENA T, RAJASEKARAN KN, GUNASEKARAN G, VISWANATHAN P., MENON VP Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-in-duced colon cancer model. Pharmacol Res 2003; 47: 133-140.